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Mass spectrometry proves under-O-glycosylation of glomeru- is the linkage between the a-anomeric carbon atom in
lar IgA1 in IgA nephropathy. N-acetylgalactosamine (GalNAc) and the hydroxy group
Background. The IgA1 molecule, which is predominantly of serine or threonine [GalNAca1-O-Ser(Thr)].deposited in glomeruli in IgA nephropathy (IgAN), is a unique
The structural variety of the sugar side chains in glyco-serum glycoprotein because it has O-glycan side chains in its
proteins is widely observed under physiological condi-hinge region. Our study was conducted to investigate the
O-glycan structure in the glomerular IgA1 in IgAN. tions. The phenomenon is called “the microheterogeneity
Methods. The IgA1 was separated from 290 renal biopsy of carbohydrate” [4]. As shown in Figure 1, the GalNAc
specimens of 278 IgAN patients and from four serum IgA1 residue in the glycans of the human IgA1 hinge may besamples (IgAN, 2; control, 2). The variety of O-glycan glyco-
extended with b1,3-linked galactose (Galb1,3GalNAc).form was determined by estimating the precise molecular
Also, sialic acid [(N-acetylneuraminic acid (NANA)]weights of the IgA1 hinge glycopeptides using matrix-assisted
laser desorption ionization time of flight mass spectrometry. could bind to Gal with a2,3 and/or to GalNAc with
Results. The peak distribution of IgA1 hinge glycopeptides a2,6 linkage. Therefore, there could be six varieties of
clearly shifted to lesser molecular weights in both glomerular
O-glycans structures in the hinge region of IgA1 (Fig. 1A).and serum IgA1 in IgAN compared with the serum IgA1 of
The IgA1 hinge region located between the Fab andcontrols. In the five major peaks of IgA1 hinge glycopeptides
in each sample, the numbers of carbohydrates composing Fc region has a proline-rich sequence (PSTPPTPSP
O-glycans (GalNAc, Gal, and NANA) in the deposited and STPPTPSPS) [5]. Within this sequence, there are nine
serum IgA1 in IgAN patients were significantly fewer than potential O-glycosylation sites (5 Ser and 4 Thr) in each
those in the serum IgA1 in the control groups.
hinge peptide, causing a variable number of O-glycanConclusion. The O-glycan side chains in the hinge of the
side chains. According to a study by Mattu et al,glomerular IgA1 were highly underglycosylated in IgAN.
O-glycans were located at Thr228, Ser230, and Ser232, whileThese results indicate that the decreased sialylation and galac-
tosylation of the IgA1 hinge glycopeptides play a crucial role O-glycan sites at Thr225 and Thr236 were partially occupied
in its glomerular deposition in IgAN. in the hinge peptide (Fig. 1B) [3].
There have been several reports analyzing the struc-
tural varieties of O-glycans in the hinge region of serum
The human IgA1 molecule, which is known to be pre- IgA1 in IgAN [6–9]. Mestecky et al [6], Allen, Harper,
dominantly deposited in glomeruli in IgA nephropathy and Feehally [7], and Tomana et al [8] found the in-
(IgAN) [1], is one of the few serum glycoproteins because creased binding of GalNAc-specific lectins to serum
it possesses O-linked oligosaccharide (O-glycan) side IgA1 in IgAN, suggesting the undergalactosylation of
chains in its hinge region [2, 3]. The majority of serum the IgA1 hinge glycopeptides. However, the precise
proteins are glycoproteins, and the sugar side chains structural definition of the defect has proved technically
linking to proteins are usually N-linked oligosaccharides difficult and remains unconfirmed. Recently, Allen et al
(N-glycans). The fundamental structure of the O-glycans precisely analyzed the O-glycan structure of serum IgA1
using fluorophore-assisted carbohydrate electrophoresis
(FACE) and demonstrated that the IgA1 O-glycanKey words: serum glycoprotein, IgA1 hinge glomerular deposition,
O-linked oligosaccharide, IgA nephropathy. chains were truncated with increased terminal GalNAc
in IgAN [10].Received for publication June 8, 2000
However, almost all of the IgA1 molecules analyzedand in revised form August 24, 2000
Accepted for publication September 14, 2000 in the previous studies were obtained from serum be-
cause of the technical limits of the sensitivity. To theÓ 2001 by the International Society of Nephrology
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Fig. 1. (A) Possible structure of O-glycans in IgA1 hinge region. There could be the six varieties of O-glycans structure in the hinge region of
IgA1. (B) Amino acid sequence of IgA1 hinge peptide. O-glycans could be located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and
Thr236 are partially occupied in the hinge peptide [3].
Table 1. Distribution of immunofluorescence pattern of 290best of our knowledge, there have been only two studies
analyzed renal specimens (%)
investigating the O-glycan structure of deposited IgA1
2 1 11 111in the glomeruli of IgAN patients (abstract; Allen et al,
IgA 0 (0%) 93 (32.1) 157 (54.1) 40 (13.8)J Am Soc Nephrol 10:506A, 1999) [9]. Both of them were
IgG 231 (79.7) 53 (18.3) 5 (1.7) 1 (0.3)analyzed by lectin binding.
IgM 81 (27.9) 207 (71.4) 2 (0.7) 0 (0)
In this study, we attempted to purify the deposited C3 4 (1.4) 202 (69.7) 79 (27.2) 5 (1.7)
C4 266 (91.7) 24 (8.3) 0 (0) 0 (0)IgA1 in the glomeruli isolated from the renal biopsy
C1q 236 (81.4) 53 (18.3) 1 (0.3) 0 (0)specimens of IgAN patients and to analyze the precise
Fibrinogen 93 (32.1) 162 (55.9) 32 (11.0) 3 (1.0)
structure of O-glycans in the hinge region of the IgA1
using matrix-assisted laser desorption ionization time of
flight mass spectrometry (MALDI-TOFMS). From our
previous study [11], it was expected that analyses using 1997 were the subjects of this study. Informed consent
MALDI-TOFMS make it possible to overcome the prob- had been obtained from each patient when they under-
lem of analyzing such a small amount of IgA. went the renal biopsy. The mean age at the time of the
renal biopsy was 36.8 6 13.4 years old; 148 of them were
male, and 130 were female. The specimens (approximateMETHODS
size of 2 to 3 mm3) that were the remains of the routine
Materials immunofluorescence (IF) study for diagnosis had been
The following materials were purchased from the stored at 2808C in OCT medium (Miles Lab., Elkhart,
sources indicated: PD-10 from Pharmacia Biotech AB IN, USA). IF patterns of each sample evaluated by Y.H.
(Uppsala, Sweden); 4-vinyl pyridine and matrix for and Y.K. at the time of the renal biopsy are listed in
MALDI-TOFMS (2,5-dihydroxybenzoic acid (DHB), Table 1.
5-methoxysalicylic acid) from Aldrich Chem. Co., Ltd. Four serum samples were also subjects of this study.
(Milwaukee, WI, USA); Jacalin-agarose from Vector Each sample was composed of sera pooled from the
Laboratories, Inc. (Burlingame, CA, USA); Goat anti- following individuals: IgAN sample (1), four biopsy-
human IgA antibody (Organon Teknika Corp. (West proven IgAN patients; IgAN (2), five IgAN patients;
Chester, PA, USA); and trypsin from Sigma Chemical control (1), four nephrotic patients with other primary
Co. (St. Louis, MO, USA). glomerulonephritis (GN) (1 membranous nephropathy),
1 lipoid nephrosis, and 2 focal glomerulosclerosis); con-
Biological materials trol (2), seven non-nephrotic patients with other primary
The 290 renal biopsy specimens obtained from 278 GN (2 non-IgAN, 3 diabetic nephropathy, 2 crescentic
patients with IgAN for routine examination in the renal GN). IgA was negative in all patients in the control group
on IF.unit of the Kitasato University Hospital from 1988 to
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Isolation of glomeruli from renal biopsy specimens melibiose as previously described [13]. The absorbance
of the eluate at 280 nm was read to detect the protein.The isolation procedure is based on the methods of
Nonspecifically bound materials were excluded by wash-Westberg and Michael [12]. Each of the frozen renal
ing with the glucose solution. The IgA1 fractions ob-biopsy specimens in OCT compound was put together in
tained by the stepwise elution with melibiose were dia-a beaker containing 100 mL of cold phosphate-buffered
lyzed against distilled water and lyophilized. In onesaline [0.01 mol/L phosphate buffer, pH 7.4, 0.15 mol/L
serum sample (IgAN 1), IgA was isolated by using theNaCl (PBS)].
antihuman IgA column (3 mL) similar to the isolationThe pooled specimens in PBS were then transferred
of the glomerular IgA.to a 100 mesh stainless steel sieve (pore size 140 m). The
tissue was forced through the sieve by moderate pressure Preparation of IgA1 hinge glycopeptides
using the bottom of a metal spoon along with repeated
These procedures were performed according to ourwashing with cold PBS (300 mL). The pressing was con-
previous studies [11, 13].tinued for about 10 minutes; the material remaining on
Preparation of S-pyridylethylated a chain from sepa-the screen was discarded. The sieved suspension was
rated IgA. The isolated IgA samples were dissolved inthen poured through a 60 mesh (pore size 230 m) sieve,
500 mL of 0.4 mol/L Tris-HCl buffer, pH 8.6, containingwhich retained a few of the large fragments, and finally
6 mol/L guanidine-HCl and 0.2 mol/L ethylenediamine-through a 250 mesh sieve (61 m opening). The material
tetraacetic acid (EDTA). To dissociate the disulfide link-retained on the fine sieve was then extensively washed
age, dithiothreitol solution (200 mg/mL) was added andwith 300 mL of cold PBS.
stirred (serum IgA, 5.0 mL/IgA mg; deposited IgA,This material was washed into a beaker, transferred
10 mL/sample). After heating at 508C for four hours,to a 50 mL plastic centrifuge tube, and centrifuged at
1.6 mL/IgA mg (deposited IgA, 10 mL/sample) of 4-vinyl120 3 g at 48C for 10 minutes. A sample of the sediment
pyridine was added, and the reaction mixture was al-was examined by phase-contrast microscopy, and the
lowed to stand for 90 minutes at room temperature. Thenumber of nonglomerular fragments per 100 glomeruli
reaction was terminated by the addition of 50 mL ofwas counted. The total number of isolated glomeruli was
2 mol/L formic acid, and the mixture was then dialyzed
also calculated. It was found that 88% of the fragments
overnight against distilled water at 48C.
were isolated glomeruli.
Preparation of IgA1 hinge glycopeptides from trypsin
digest of IgA1 molecules. The dissociated and S-pyridyl-Elution of IgA from isolated glomeruli
ethylated IgA1 molecules were dissolved in 160 mL of
To elute the deposited IgA, the pellet of the isolated 50 mmol/L Tris-HCl buffer, pH 8.0, containing 2 mol/L
glomeruli was suspended in 10 mL of PBS solution con- urea. Twenty microliters of trypsin solution (10 mg
taining 6 mol/L urea and was incubated for 90 minutes trypsin/20 mL of the previously mentioned buffer) and
at 378C with shaking. The solution was then gently centri- 20 mL of 0.1 mol/L CaCl2 were added, and the reaction
fuged (120 3 g for 10 min). The supernatant was dialyzed mixture was incubated overnight at 378C. The trypsin
against PBS overnight at 48C. digest was made up to 2 mL by adding PBS, pH 7.4. The
sample was applied to a Jacalin-agarose column (2 mL),Sample preparation of IgA
and the passed fraction was eluted with 20 mL of the
Isolation of eluted IgA from glomeruli. To perform previously mentioned buffer. After further washing the
50% ammonium sulfate precipitation, the dialyzed su- column with 20 mL of 0.8 mol/L glucose, the a1 hinge
pernatant containing deposited IgA was mixed with an glycopeptide fraction was eluted with 6 mL of 0.1 mol/L
equal volume of saturated ammonium sulfate. After melibiose in the buffer. In our previous study, it was
dissolving the precipitate with 5 mL of PBS, the solu- established by the Edman degradation method that the
tion was applied to the anti-IgA antibody coupled acti- following 33mer IgA1 fragments containing IgA1 hinge
vated sepharose 4 B column (1 mL). After the column glycopeptides were isolated by these procedures [11]
was thoroughly washed with PBS, IgA was eluted with HYTNPSQDVTVPCPVPSTPPTPSPSTPPTPSPS,
2 mol/L urea. The solution was then applied on a PD where the italicized sequence indicates hinge peptide
10 (5 mL) column to delete the salts and lyophilized. core.
Purification of serum IgA. Approximately 5 mL of Purification of the glycopeptides by high-performance
serum from each subject were also mixed with an equal liquid chromatography (HPLC) was carried out using
volume of saturated ammonium sulfate, and the precipi- a Cosmosil 5C18-300 column (Nacalai Tesque, 4.6 3
tate obtained was dissolved, dialyzed against PBS, and 150 mm). Elution was carried out using a linear gradient
applied to the Jacalin-agarose column (3 mL). After the for 60 minutes from 0 to 90% acetonitrile in 0.1% triflu-
column was thoroughly washed with PBS, it was first oracetic acid (TFA) with a 0.5 mL/min flow rate. Detec-
tion was performed by monitoring the ultraviolet absorp-eluted with 0.8 mol/L glucose and then with 0.1 mol/L
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Fig. 2. High pressure liquid chromatography
(HPLC) chromatogram of isolated 33mer
IgA1 fragments containing hinge glycopep-
tides. A definite peak composed of the IgA1
hinge glycopeptides is observed around 20
minutes in all serum samples.
tion at 220 nm. Under these chromatographic conditions, x GalNAc 1 y Gal 1 z NANA. In this formula, the
the definite peak composed of the IgA1 hinge glycopep- molecular weights of each factor were as follows: 33mer
tides was observed around 20 minutes in all the serum HP, 3475.7; GalNAc, 203.2, Gal, 162.2; and NANA, 291.3.
samples (Fig. 2). The material eluted at the peak position The combination number of x, y, and z was determined
of the hinge was collected and lyophilized. As expected, from the molecular weights.
the content of the isolated hinge of glomerular IgA1 was Each peak in the mass spectrum was regarded as the
so small that no definite peak was observed on the HPLC corresponding glycoform of the hinge, if the measured
chromatogram. Therefore, the 19- to 21-minute fractions molecular weight of the peak was consistent with the
were obtained and lyophilized in the same manner. theoretical molecular weight of the hinge structure
within a 0.5% error.
MALDI-TOFMS analyses To perform the further analyses, the largest five peaks
The isolated hinge glycopeptides were analyzed by in each of the five IgA1 samples (total 25 peaks) were
MALDI-TOFMS in the positive ion mode to suppress selected. Since eight peaks overlapped among the sam-
the production of the adduct ion. The mass spectrometer ples, 17 peaks were studied. The peaks are underlined
used in this work was a Voyager-DE (PerSeptive Biosys- in the Table 2, and labeled alphabetically (a) to (e) in
tems, Framingham, MA, USA). The matrix used was a asialo-type and (1) to (12) in sialo-type structure (Fig.
mixture of saturated solution of 2,5-dihydroxy benzoic 3 and Table 2). The number of GalNAc, Gal, and NANA
acid (DHB) and 5-methoxy salicylic acid in the ratio of of the 17 major peaks was compared among the glomeru-
9:1 in 50% acetonitrile and 0.1% TFA/H2O. The condi- lar IgA (Glom. IgA) and serum IgA of IgAN (SN IgA)
tions of the mass spectrometry were as follows: accelerat- and that of the controls (SC IgA) using Mann–Whitney’s
ing voltage of 20,000 and grid voltage of 94.0%; 256 shots U-test. As both serum groups had two samples, the analy-
were then summed. sis numbers were 5 in Glom. IgA and 10 in the serum
The calibration of m/z was performed using adreno- groups.
corticoid hormone (ACTH; m/z, 3661) and bovine insulin It was regarded as statistically significant if the P value
(5737). was less than 0.05.
Data analyses
RESULTSThe distribution of the MALDI-TOFMS peaks was
Figure 3 shows the actual mass spectra of the IgA1compared among the five samples. The molecular size
hinge in the five samples. It was obvious that the distribu-(m/z) of each peak was estimated, and the structure of
tion of the peaks of glomerular IgA and of the IgANthe carbohydrate side chains in the IgA1 hinge (number
groups was shifted to a lower molecular weight rangeof x, y, and z in the formula shown later in this article)
compared with that of the control groups.was determined by referring to the corresponding theo-
All of the assigned peaks in each IgA group are listedretical molecular weights calculated from the numbers
in Table 2. Among the 17 major peaks that were theof GalNAc, Gal, or sialic acid (NANA) according to
largest five peaks in any of the five IgA1 samples (under-the following formula: molecular weight 5 33mer IgA1
fragment containing the hinge peptide (33mer HP) 1 lined in Table 2), it was noted that four of the five main
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Table 2. Distribution of assigned peaks of IgA1 hinge glycopeptides
Glycoform
Measured molecular wt of each peak
Serum IgA1
Theoretical
x y z molecular wt Dep.IgA1 IgAN(1) IgAN(2) Cont.(1) Cont.(2)
Asialo-type
3 2 0 4410 4389 4409 4404 2 2
3 3 0 4572 2 4573 2 2 2
(a) 4 0 0 4289 4287 2 2 2 2
(b) 4 2 0 4613 4602 4612 4608 2 2
(c) 4 3 0 4775 2 4774 4768 4771 4769
(d) 4 4 0 4937 4911 4936 4929 4931 4931
5 3 0 4978 2 4992 4974 4975 4975
(e) 6 2 0 5019 5015 2 2 2 2
Sialo-type
3 2 1 4701 2 4702 4692 2 2
(1) 3 3 1 4863 2 4862 2 2 2
(2) 3 3 2 5154 5152 5152 5147 2 2
(3) 4 2 1 4904 4885 4904 4900 2 2
(4) 4 2 2 5195 2 2 5191 2 2
(5) 4 3 1 5066 5070 5065 5058 5063 5062
(6) 4 3 2 5358 5364 5357 5351 5356 5350
4 3 3 5649 2 2 2 2 5665
(7) 4 4 1 5228 2 5227 5221 5224 5224
4 4 2 5520 2 5518 5515 5514 5512
4 4 4 6102 6100 2 2 2 2
5 2 1 5107 2 5107 5101 2 2
5 3 1 5270 2 5271 5265 5267 5265
(8) 5 3 2 5561 5562 5562 5554 5576 5576
(9) 5 3 3 5852 2 5854 2 5867 5866
5 4 1 5432 2 2 2 5416 5412
(10) 5 4 2 5723 2 2 2 5739 5736
(11) 5 4 3 6014 2 2 2 6030 6028
5 4 4 6305 2 2 2 6323 6316
5 5 3 6176 2 2 2 6158 6158
6 3 2 5764 2 2 2 5783 5777
(12) 6 3 3 6055 2 2 2 6073 6067
6 4 1 5635 5632 2 5643 5624 5618
6 4 2 5926 2 2 2 5910 5912
6 4 3 6217 6218 2 2 2 2
6 5 3 6380 2 2 2 6369 6360
6 6 2 6250 2 2 2 6277 6275
Minus signs mean not determined. Molecular weight 5 33mer hinge peptide 1 x GalNAc 1 y Gal 1 z NANA 5 3475.7 1 203.2 x 1 162.2 y 1 291.3 z. The
observed peaks in every group of IgA1 are listed. In the 17 major peaks underlined, note that four of the five main peaks (peaks a, b, d and e) are asialo-type in
the glomerular IgA1 hinge glycopeptides.
(a–e): Assigned major peaks of asialo-type hinge in each group.
(1–12): Assigned major peaks of sialo-type hinge.
peaks (peak a, b, d, and e) were asialo-type (Z 5 0) in serum IgA1 in IgAN were fewer than those in serum
the glomerular IgA1 hinge glycopeptides. Figure 4 shows IgA1 in the control group.
a comparison of the number of GalNAc, Gal, and sialic Urea was used for isolating deposited IgA from glo-
acid residues of the major peaks among the three IgA meruli. Since the effect of the treatment on the glycoform
groups. The number of GalNAc was significantly de- of the glom. IgA1 hinge was considerable, the O-glycan
creased in the SN IgA group (mean 6 SD; 3.8 6 0.4) glycoform was compared between urea-treated and non-
compared with that of the SC IgA group (5.1 6 0.6, P , treated IgA1 hinge glycopeptides. There was no signifi-
0.001). The Gal content of Glom. IgA (2.0 6 1.4) was cant difference between them (data not shown).
significantly lower than that of SC IgA (3.4 6 0.5, P ,
0.05). The most striking difference was found in sialic
DISCUSSIONacid, which was significantly decreased in Glom. IgA
IgA nephropathy is defined as mesangial proliferative(0.2 6 0.4) compared with those of both the SN (1.2 6
glomerulonephritis with the deposition of IgA and C3 in0.8, P , 0.05) and SC IgA groups (2.4 6 0.7, P , 0.005).
the mesangium [14]. Therefore, circulating IgA immuneThe number of SN IgA was also significantly smaller
complexes are thought to be involved in the pathogenesisthan that of SC IgA (P , 0.01). Overall, numbers of
carbohydrates composing O-glycans in deposited and of IgAN [15]. However, since deposited IgA appears to
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Fig. 3. Mass spectra of IgA1 hinge in five samples. The distribution of the peaks of glomerular IgA1 and IgA1 of the IgAN groups (upper
3 graphs) shifts to a molecular weight lower than in control groups (lower 2 graphs).
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Fig. 4. Numbers of GalNAc, Gal, and sialic
acid (NANA) residues in five main peaks in
each group. (A; number of GalNAc) The
mean numbers (6 SD) of glomerular IgA1
(Glom. IgA; d), serum IgA1 of IgAN (SN
IgA; s), and serum IgA1 of control (SC IgA;
j) groups are 4.4 6 0.9, 3.8 6 0.4, and 5.1 6
0.6, respectively. The number is significantly
decreased in SN IgA group compared with
that of SC IgA group. (B; Gal) The mean
numbers (6 SD) of Glom., SN, and SC IgA
groups are 2.0 6 1.4, 3.0 6 0.5, and 3.4 6
0.5, respectively. In Glom. IgA, the number
is significantly fewer than that of SC IgA. (C;
sialic acid) The mean numbers (6 SD) of
Glom., SN, and SC IgA groups are 0.2 6 0.4,
1.2 6 0.8, and 2.4 6 0.7, respectively. The
content is significantly decreased in Glom. IgA
group compared with those of both SN and
SC IgA groups. The number of the SA IgA
group is also significantly smaller than that of
the SC IgA. The overall numbers of carbohy-
drates (GalNAc, Gal, and sialic acid) in the
deposited and serum IgA1 in IgAN patients
are fewer than those in the serum IgA1 in the
control groups.
be polyclonal, displaying no apparent antigen restriction, in the specific release of the Galb1,3GalNAc side chains
from the IgA1 hinge by gas-phase hydrazinolysis [21],we have suggested that physicochemical abnormalities
of IgA might be ascribed to its glomerular deposition in and found an increase in the asialo-Galb1,3GalNAc resi-
due in the patients with IgAN [16]. However, these meth-a nonimmunologic manner [16–19].
In this study, we present the first information of precise ods failed to find any free GalNAc residue. Therefore,
we could not obtain any information about the contentstructure of O-glycans in the deposited IgA1 in the glo-
meruli of IgAN by MALDI-TOFMS analyses. In our of Gal, which was bound to the outer side of GalNAc.
Recently, a few reports have appeared in which thisprevious studies using an early MALDI-TOFMS model
[11, 13, 20], it was impossible to analyze the native IgA1 problem was overcome using physicochemical methods.
Allen et al precisely analyzed the O-glycan structure ofhinge region. Only the molecular weights of the IgA1
fragments treated by the exo-glycosidases (neuramini- serum IgA1 using FACE and demonstrated that the
IgA1 O-glycans chains were truncated with increaseddase, b-galactosidase, and N-acetyl galactosaminidase)
could be estimated. In the present study, we could di- terminal GalNAc in IgAN [10]. In our most recent study,
Odani et al developed a method for the direct analysisrectly analyze the native IgA1 hinge using the newer
MALDI-TOFMS apparatus, which had a enough capac- of the IgA1 hinge using electrospray ionization/liquid
chromatography/mass spectrometry (ESI/LC/MS) andity for estimating the molecular weights of the native
IgA1 hinge glycopeptides. observed a decreased sialylation and galactosylation of
the hinge glycopeptides of serum IgA1 in IgAN [22].We could differentiate the structure of the IgA1 hinge
glycopeptides in the patients with IgAN from those in However, the physicochemical techniques such as hy-
drazinolysis, FACE, or ESI/LC/MS were unable to ana-the non-IgAN controls. The results supported the series
of previous studies [6–11], indicating that the IgA1 hinge lyze the O-glycan structure of the deposited IgA1 in the
glomeruli because of its small quantity. The MALDI-of IgAN patients was underglycosylated. The informa-
tion obtained in these previous studies had been rather TOFMS apparatus used in our current study, however,
had enough sensitivity to obtain the information fromindirect and limited. The majority of the data were ob-
tained by the binding capacity of IgA1 to the lectins such a small IgA1 sample. According to the manufactur-
er’s instructions, the apparatus is capable of estimatingrecognizing each carbohydrate part of O-glycans in the
IgA1 hinge. In the biochemical analyses, we succeeded molecular weights from 50 fmol/L of a calibration sample
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